lifestyle.side.cr

Author: Monopar Therapeutics Inc.

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

April 19, 2026
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

March 27, 2026
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

March 2, 2026